IL-6, but not TNF-α, increases plasma YKL-40 in human subjects
Plasma levels of YKL-40 are elevated in patients with systemic infection, inflammatory disorders and cancer. Both monocytes/macrophages, neutrophils, and cancer cells have the capacity to produce YKL-40, but the regulation during the inflammatory response is unknown. To study the possible role of in...
Saved in:
Published in | Cytokine (Philadelphia, Pa.) Vol. 55; no. 1; pp. 152 - 155 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.07.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Plasma levels of YKL-40 are elevated in patients with systemic infection, inflammatory disorders and cancer. Both monocytes/macrophages, neutrophils, and cancer cells have the capacity to produce YKL-40, but the regulation during the inflammatory response is unknown. To study the possible role of interleukin-6 (IL-6) and tumor necrosis factor (TNF)-α in the regulation of YKL-40 plasma levels, we included healthy men, who received either recombinant human (rh)IL-6 (
n
=
6), rhTNF-α (
n
=
8) or vehicle (
n
=
7) for 3
h. The plasma levels of IL-6 and TNF-α reached ∼150 and ∼18
pg/ml, respectively, during the infusions. Following the IL-6 infusion, the plasma level of YKL-40 increased from ∼30 to ∼57
ng/ml (
p
<
0.05) at 24
h, and returned to normal values after 48
h. The plasma level of YKL-40 did not change during TNF-α infusion or infusion of vehicle. These data demonstrate that IL-6, but not TNF-α, has a key-role in the regulation of plasma YKL-40 levels during inflammation. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
ISSN: | 1043-4666 1096-0023 |
DOI: | 10.1016/j.cyto.2011.03.014 |